155 related articles for article (PubMed ID: 37551766)
1. Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Chen Z; Zhou J; Liu Y; Ni H; Zhou B
Drug Dev Res; 2023 Nov; 84(7):1482-1495. PubMed ID: 37551766
[TBL] [Abstract][Full Text] [Related]
2. Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
Fu T; Yang Y; Mu Z; Sun R; Li X; Dong J
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):680-692. PubMed ID: 34435542
[TBL] [Abstract][Full Text] [Related]
3. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
4. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis.
Yang G; Li T; Liu J; Quan Z; Liu M; Guo Y; Wu Y; Ou L; Wu X; Zheng Y
Genomics; 2023 Mar; 115(2):110599. PubMed ID: 36889366
[TBL] [Abstract][Full Text] [Related]
5. MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights.
Kortam MA; Elfar N; Shaker OG; El-Boghdady NA; Abd-Elmawla MA
ACS Chem Neurosci; 2023 Mar; 14(6):1107-1118. PubMed ID: 36878000
[TBL] [Abstract][Full Text] [Related]
6. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
7. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
8. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
9. lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Zhou J; Xu N; Liu B; Wang C; He Z; Lenahan C; Tang W; Zeng H; Guo H
Cancer Sci; 2022 Aug; 113(8):2681-2692. PubMed ID: 35637600
[TBL] [Abstract][Full Text] [Related]
10. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
11. LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma.
Yang R; Chen Z; Ao S; Liang L; Chen Z; Duan X; Zeng G; Deng T
Cell Signal; 2024 Jan; 113():110954. PubMed ID: 38084836
[TBL] [Abstract][Full Text] [Related]
12. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
13. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MAGI2-As3 Suppresses the Proliferation and Invasion of Cervical Cancer by Sponging MiR-15b.
Chai Y; Wang L; Qu Y; Hu Z
J Healthc Eng; 2022; 2022():9707206. PubMed ID: 35126958
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis.
Shen D; Xu J; Cao X; Cao X; Tan H; Deng H
Cancer Biomark; 2021; 30(2):155-165. PubMed ID: 33104021
[TBL] [Abstract][Full Text] [Related]
17. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
18. LncRNA MAGI2-AS3 Inhibits Prostate Cancer Progression by Targeting the miR-142-3p.
Hu R; Wu P; Liu J
Horm Metab Res; 2022 Nov; 54(11):754-759. PubMed ID: 35944561
[TBL] [Abstract][Full Text] [Related]
19. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25.
Sui Y; Chi W; Feng L; Jiang J
BMC Pulm Med; 2020 Mar; 20(1):59. PubMed ID: 32138716
[TBL] [Abstract][Full Text] [Related]
20. GLIDR promotes the progression of glioma by regulating the miR-4677-3p/MAGI2 axis.
Yu Q; Li X; Feng T
Exp Cell Res; 2021 Sep; 406(1):112726. PubMed ID: 34237299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
